ALQ – Macquarie rates the stock as Outperform
The Outperform rating is retained and the target price increases to $14.70 from $14.00.
Read MoreThe Outperform rating is retained and the target price increases to $14.70 from $14.00.
Read MoreCredit Suisse has raised its FY22 EPS forecast by 2.6% and increases the target price to $15.05 from $14.07. Outperform.
Read MoreThe Outperform rating is retained and the target price increases to $14.70 from $14.10.
Read MoreALS will pay a sharply higher dividend for the September half, with the Brisbane-based testing group boosting underlying net profit more than 57% and seeing more of the same moving forward.
Read MoreMorgans raises the target to $13.17 from $12.45 and retains a Hold rating.
Read MoreOutperform rating maintained. Target is $13.80.
Read MoreUBS retains a Neutral rating and raises the target to $13.00 from $12.25.
Read MoreCredit Suisse retains an Outperform rating and increases the target to $13.45 from $10.40.
Read MoreShares in global testing lab operator ALS surged more than 12% yesterday to a new year’s high as the company played catch up for its shareholders with a sharply higher final payout.
Read MoreAs the outlook for minerals exploration improves and concerns over the economic impact of the pandemic ease, the laboratory services of ALS Ltd will be in demand.
Read MoreALS Ltd will acquire Investiga, a pharmaceutical testing company based in the Americas. UBS retains a Neutral rating and $9.90 target and believes the stock adequately prices in the global improvement.
Read MoreAn upbeat trading update for the six months to March 31 from Brisbane-based global testing group ALS came with news of a small acquisition in Brazil.
Read MoreALS has invested in additional geochemistry capacity as the cycle for global mineral exploration ramps up again, providing an improved earnings outlook.
Read MoreTesting and inspection business ALS has chopped interim dividend by a quarter after its first-half result produced lower revenue and earnings, with more of the same to come.
Read MoreALS’s first-quarter revenues were down -10% versus the June quarter due to covid-19 restrictions.
Read MoreMorgan Stanley notes while ALS has lagged its global peers over the last 1-2 years, there is upside potential for if the expansion of its Life Sciences business continues.
Read MoreThe broker notes lead indicators for ALS’ geochem business are improving, with Canadian resource raisings up 66% in the first half of 2020 and Australian raisings also lifting off low levels. Typically there is a 2-3 month lag for resource raisings to flow into additional exploration activity.
Read MoreALS Ltd has acted quickly to manage the economic downturn but a robust recovery in sample flows and testing is expected as lockdowns measures are unwound.
Read MoreFY20 net profit was slightly ahead of UBS estimates. The company has reiterated recent commentary regarding trading and provided no formal FY21 guidance.
Read MoreShares in Brisbane-based global testing group, ALS Ltd rose nearly 3% despite the group revealing a weak 2019-20 result and lower final dividend.
Read MoreWoodside Petroleum is bracing for “unprecedented circumstances”, global testing giant ALS is marshaling its financial forces to survive the impact of COVID-19 while South32 plans slash capital expenditure and has suspended its on-market buyback.
Read MoreBrisbane-based multinational testing group, ALS saw its shares buck what was a very, very weak market yesterday after reporting better than forecast half-year earnings, a higher dividend and an upbeat earnings forecast for the year to next March.
Read MoreWhile the stock is priced for a recovery in geochemistry Credit Suisse finds little evidence this is occurring. The focus at the result is likely to be on the volume growth in geochemistry and continued margin improvement in life sciences.
Read MoreA collection of mining services companies beginning to experience some attractive breakouts that point to these flow-on affects from mining activity translating to a sustained increase in earnings.
Read MoreThe first half guidance issued at the AGM was slightly below Morgans’ expectations. The broker believes peak commodities-driven growth is now behind the company and the health of the exploration and mining capital raisings remain key to the performance in FY20.
Read MoreFY19 net profit was in line with Credit Suisse estimates. Revenue growth occurred across all segments and margins improved in life sciences for the first time in six years.
Read MoreA good result from Brisbane-based global testing group ALS yesterday with 27.3% lift in after-tax net profit to $181 million for the 2018-19 year ending March 31.
Read MoreMacquarie expects earnings growth will prove to be robust when the company reports its FY19 result on May 21. Life Sciences produced strong sequential improvement in the first half and the broker expects a margin expansion of 130 basis points in the second half.
Read MoreThe rebound in global resources and in the wider economy has seen the Brisbane-based global testing giant, ALS Limited boost interim dividend by a third after lifting earnings by 30% on an underlying basis to $93.3 million for the September half of its 2018-19 financial year.
Read MoreShares in Brisbane-based global testing giant, ALS Ltd surged yesterday, adding more than 11% in value after the company’s annual meeting heard an upbeat outlook for the first half of the 2018-19 financial year.
Read MoreBrisbane-based testing group, ALS Ltd has lifted final dividend on top of a higher interim after reporting an improved underlying performance for 2017-18.
Read MoreYou can understand why Brisbane-based testing group, ALS Limited will offer shareholders a $175 million buy back, as well as a higher interim dividend after announcing an underlying net profit after tax of $70.1 million for the six months to September 30, 2017. While the company reported a solid underlying result, the after tax result including one offs saw the impact of more impairments on its assets – this time in its coal testing division.
Read MoreShares in Brisbane based testing group ALS jumped nearly 12% as investors reacted favourably to the release of the 216-17 results late on Tuesday night.
Read MoreThe news wasn’t encouraging yesterday for shareholders in Brisbane-based testing giant, ALS (ALQ), which only a month and a bit ago rejected an unwanted $2.7 billion takeover approach.
Read MoreIs the takeover offer for ALS a replay of Treasury Wine Estates and the way it fought off numerous approaches from private equity groups trying to buy the company before a turnaround became apparent – a rebound that has seen Treasury shares double from the original offer price?
Read MoreAnother global Australian company is under takeover threat.
Read MoreBrisbane-based testing group ALS Ltd (ALQ) saw its shares hammered more than 11% lower yesterday as investors gave the full year results and weak outlook the thumbs down.
Read MoreShares in testing giant ALS (ALQ) shook off a small first half downgrade revealed at yesterday’s annual meeting in Brisbane to close up more than 3%.
Read MoreBrisbane-based testing services group ALS Limited (ALQ) is not letting the downturn in the mining, oil and gas and other areas of the economy (such as water) and a loss in 2014-15 stop it from continuing on its growth plan.
Read More